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Abstract
Aims and Objective: To study the role of myoepithelial (ME) cells in distinguishing benign,
proliferative breast diseases (PBD) and frank malignant breast lesions.
Materials and methods: In this study, histology proven 71 cases of  fi ne  need le aspirati on
cytology (FNAC) of palpable breast lesions were selected. There were 30 invasive carcinomas (24
infiltrating duct carcinoma and 6 infiltrating lobular carcinoma), 25 cases of benign lesion (21
fibroadenomas and 4 fibrocystic lesions) and 11 proliferative breast diseases (other than carcinoma
in situ) and five cases of carcinoma in situ. The number of ME cells were estimated in respect to
1000 ductal cells. In every case at least 20 high power fields (× 40) were studied. Quantitative
estimation of ME cell was correlated with the final diagnosis. Corresponding histopathology cases
were also evaluated for diagnostic confirmation along with the pattern of distribution of ME cells.
The ME cells were also quantitated on histopathology sections on smooth muscle actin (SMA)
immunostained sections.
Results: The mean number of ME cells per 1000 ductal cells on cytology smears was 5.1 ± 5.5,
30.8 ± 25, 28.3 ± 20.2, and 38.4 ± 38.8 in malignant, carcinoma in situ, PBD and benign breast
lesions respectively. The non parametric Mann Whitney test showed significant difference in
number of the ME cells between benign and malignant groups (p < .000), PBD and malignant groups
(p < .000) and carcinoma in situ and malignant group (p < .001). However, it was insignificant
between benign and PBD group, and PBD and carcinoma in situ (p > .01). In SMA stained
histopathology sections, ME cell in benign, PBD, carcinoma in situ and malignant cases were 741.12
± 248, 238 ± 172, 121.6 ± 115 and 15.6 ± 25.1 respectively. Statistical analysis showed significantly
different number of ME cell between benign versus PBD group, carcinoma in situ and malignant
group. It was also significant between PBD versus malignant, and carcinoma in situ versus malignant
(p < .001, Mann Whitney test). However number of ME cell was not significant between PBD versus
carcinoma in situ.
Conclusion: The number of ME cell in breast lesions may be helpful in distinguishing PBD versus
invasive malignant tumors on FNAC smears. However it is not helpful to distinguish benign lesions
versus PBD.
Published: 21 April 2008
CytoJournal 2008, 5:9 doi:10.1186/1742-6413-5-9
Received: 7 February 2008
Accepted: 21 April 2008
This article is available from: http://www.cytojournal.com/content/5/1/9
© 2008 Pattari et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.CytoJournal 2008, 5:9 http://www.cytojournal.com/content/5/1/9
Page 2 of 5
(page number not for citation purposes)
Background
Fine needle aspiration cytology (FNAC) is an important
tool for rapid and accurate diagnosis of various benign
and malignant breast lesions with high sensitivity and
specificity [1-4]. However in certain occasion it is difficult
to provide a definitive diagnosis in breast neoplasm with
the help of FNAC. This is particularly true in proliferative
breast diseases (PBD), and certain types of carcinomas
such as tubular carcinoma and lobular carcinomas [5-7].
The presence of myoepithelial cell (ME) has long been
recognized as a prominent feature of benign breast dis-
eases [8]. However its presence in proliferative breast dis-
eases has rarely been explored particularly in FNAC
smears [8-11]. In this present paper we studied the role of
quantitation of ME cells in distinguishing benign, PBD
and frank malignant breast lesions.
Materials and methods
In this study, histology proven 71 cases of FNAC of palpa-
ble breast lesions were selected. There were 30 invasive
malignant tumors (24 cases of infiltrating duct carcinoma
and 6 cases of infiltrating lobular carcinoma), 25 cases of
benign lesion (21 fibroadenomas and 4 fibrocystic
lesions) and 11 proliferative breast diseases and five cases
of carcinoma in situ (CIS). Both malignant and benign
breast lesions were selected randomly. FNAC smears of all
the histopathology proven PBD cases diagnosed in last
four years were selected for this study. The PBD cases were
classified as described by Page DL et al [6]. The carcinoma
in situ cases were classified as described by Holland R et al
[12]. In all the cases both May Grunwald Giemsa and hae-
matoxylin and eosin stained smears were studied. The ME
cells in FNAC smears were identified as oval to bipolar
cells with scanty cytoplasm and elongated densely stained
nuclei. The number of ME cells were estimated in respect
to 1000 ductal cells. In every case at least 20 high power
fields (× 40) were studied. Quantitative estimation of ME
cell was correlated with the final diagnosis. Correspond-
ing histopathology cases were also evaluated for diagnos-
tic confirmation along with the pattern of distribution
and counting of ME cells on smooth muscle actin (SMA)
immunostained sections (DAKO muscle actin, HHF 35).
Results
The distribution of cases was shown in table 1. In group
A, there were 25 benign breast lesions comprised of 21
cases of fibroadenoma (FA) and four cases of fibrocystic
diseases. In group B, there were 11 cases of PBD com-
prised of mild hyperplasia (5), moderate hyperplasia (4),
and atypical ductal hyperplasia (2). In group C there were
five cases of carcinoma in situ (5), out of which three were
three high grade and one each intermediate grade and low
grade tumor. In group D, there were 30 malignant tumors
comprised of 24 cases of infiltrating duct carcinoma and 6
cases of infiltrating lobular carcinoma.
The ME cells were distributed as scattered singly in the
background in between the epithelial cell clusters and
within the epithelial cell clusters (figure 1, 2, 3). The mean
number of ME cells per 1000 ductal cells on cytology
smears was 5.1 ± 5.5, 30.8 ± 25, 28.3 ± 20.2, and 38.4 ±
38.8 in malignant, carcinoma in situ, PBD and benign
breast lesions respectively (Table 2). The non parametric
Mann Whitney test showed significant difference in
number of the ME cells between benign and malignant
Table 1: Distribution of cases
Diagnosis Number of cases
Diagnosis Number of cases
Fibroadenoma 21
Fibrocystic cases 4
Group B, Proliferative breast disease
Mild Hyperplasia 5
Moderate Hyperplasia 4
Atypical ductal Hyperplasia 2
Group C, Carcinoma in situ
Carcinoma in situ 5
Group D, Invasive malignant tumor
Infiltrating duct carcinoma 24
Infiltrating lobular carcinoma 6
Table 2: Mean number of myoepithelial cells in cytology smear
Diagnostic groups Number of cases Mean Standard deviation (±)
Group A, Benign 25 38.4 38.8
Group B, Proliferative breast disease 11 28.3 20.2
Group C, Carcinoma in situ 5 30.8 25.0
Group D, Invasive malignant tumor 30 5.1 5.5
Mann Whitney's U Test
Group A and Group B, p = 0.685, not significant
Group A and Group C, p = 0.706, not significant
Group A and Group D, p = 0.000, significant
Group B and Group C, P = 0.913, not significant
Group B and Group D, p = .000, significant
Group C and Group D, p = 0.001, significantCytoJournal 2008, 5:9 http://www.cytojournal.com/content/5/1/9
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groups (p < .000), PBD and malignant groups (p < .000)
and carcinoma in situ and malignant group (p < .001).
However, the number of the ME cells was insignificant
between benign and PBD group, and PBD and carcinoma
in situ (p > .01).
The SMA staining gave consistent staining of ME cells,
which were distributed as a continuous circumferential
layer around the ducts and acini of normal breast tissue.
The uniformly circumferential staining pattern was main-
tained in FA, which however became compressed in ducts
with marked invagination due to stromal connective tis-
sue overgrowth (figure 4). In PBD, the circumferential pat-
tern of staining was mostly maintained. The uniformity of
distribution and number of stained cells varied depending
upon the histological spectrum of the lesion. In mild or
moderate PBD, the staining was uniformly circumferen-
tial (figure 5). In carcinoma in situ, the affected ducts and
acini showed interrupted pattern of staining with marked
thinning. In IDC, there was almost complete absence of
SMA stained cells around the tumor cells. In smooth mus-
cle actin stained histopathology sections, ME cell in
benign, PBD, carcinoma in situ and malignant cases were
741.12 ± 248, 238 ± 172, 121.6 ± 115 and 15.6 ± 25.1
respectively (Table 3). Statistical analysis showed signifi-
cantly different number of ME cell between benign versus
PBD group, carcinoma in situ and malignant group
(Mann Whitney test). It was also significant between PBD
versus malignant, and carcinoma in situ versus malignant
(p < .001, Mann Whitney test). However number of ME
cell was not significantly different between PBD versus
carcinoma in situ.
Discussion
Ductal system of breast is composed of epithelial cells, ME
cells and intermediate or basal clear cells. In FNAC
smears, ME cells are identified as oval to elongated bipolar
cells with stripped of cytoplasm. In this present study, the
number of ME cells in FNAC smears was significantly
decreased between benign and malignant lesions as well
as between PBD and malignant lesions, but the difference
was not significant between benign and PBD. Yu et al [8]
also quantified the number of ME cells per 40 high power
Many scattered myoepithelial cells in cytology smear of  fibroadenoma Figure 1
Many scattered myoepithelial cells in cytology smear of 
fibroadenoma. (Haematoxylin and Eosin × 480).
Occasional myoepithelial cells in cytology smear of moderate  hyperplasia Figure 2
Occasional myoepithelial cells in cytology smear of moderate 
hyperplasia. (Haematoxylin and Eosin × 480).
Table 3: Mean number of myoepithelial cells in SMA stained histology sections
Diagnostic groups Number of cases Mean Standard deviation (±)
Group A, Benign 25 741.12 248
Group B, Proliferative breast disease 11 238 172
Group C, Carcinoma in situ 5 121.6 115
Group D, Invasive malignant tumor 30 15.6 25.1
Mann Whitney's U Test
Group A and Group B, p = 0.000, significant
Group A and Group C, p = 0.000, significant
Group A and Group D, p = 0.000, significant
Group B and Group C, P = 0.234, not significant
Group B and Group D, p = .000, significant
Group C and Group D, p = 0.000, significantCytoJournal 2008, 5:9 http://www.cytojournal.com/content/5/1/9
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field and showed that single ME cell could be seen in both
benign and malignant lesions. They noted that paired ME
cells was a feature of benign lesions only and this was not
present in malignant lesions. In the present study, pairing
of ME cell was not a significant observation even in
benign lesion.
Masood S et al [13] demonstrated significant difference of
number of ME cell in benign versus malignant tumors.
Unlike this study, we compared the number of ME cell
between PBD with benign and malignant lesions.
Bofin AM et al [10] compared the cytologic features of
benign PBD, DCIS and invasive carcinoma on FNAC
smears. They noted that nuclear morphology, myoepithe-
lial cells, signs of invasion and degree of cellular differen-
tiation are the most important discriminating factors to
distinguish between different groups of lesions. Similar to
the present study they also noted that ME cells are virtu-
ally absent or markedly reduced in invasive carcinoma
compared to DCIS lesions. Bofin AM et al only labeled the
presence or absence of ME cells. However we tried to
quantify the number of such cells on FNAC smears [10].
The number of ME cell was helpful in distinguishing PBD
and malignant lesions but not between PBD and benign
lesion. In histopathology sections stained by SMA, the
number of ME cell was significantly different between
benign and PBD, benign and malignant; as well as
between PBD and malignant lesions. Thus ME cell differ-
entiation is present in benign and proliferative disorders.
However, this differentiation is lost in carcinoma [14]. In
histopathology, a statistically significant difference in ME
cell number was noted between benign and PBD, How-
ever, in cytology this difference was not statistically signif-
icant. This may be because of the limitation of proper
sampling from the representative area in FNAC smears. It
was easier to select out the representative areas for count-
ing, whereas this was not possible in FNAC smears.
Confirmation of ME cells on routine cytology or histology
can be done with the help of immunostaining. We per-
formed SMA immunostaining. However these cells can
also be identified by S-100[15], calponin [16], h-calde-
smin[16,17], smooth muscle heavy chain (SMMHC) anti-
bodies [16,17] and CD10 [18]. Foschini MP et al [16]
showed that SMMHC is more specific for ME cells in
breast.
Myoepithelial cells in SMA stained histology section of mild  hyperplasia Figure 5
Myoepithelial cells in SMA stained histology section of mild 
hyperplasia. (Smooth muscle actin × 480).
Circumferential presence of myoepithelial cells in SMA  stained histology section of fibroadenoma Figure 4
Circumferential presence of myoepithelial cells in SMA 
stained histology section of fibroadenoma. (Smooth muscle 
actin × 480).
Myoepithelial cells in cytology smear of carcinoma in situ Figure 3
Myoepithelial cells in cytology smear of carcinoma in situ. 
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Atypical ductal hyperplasia is a pre-malignant lesion and
carcinoma in situ is considered as pre-invasive malignant
lesion [19]. It is of great clinical importance to identify
accurately these lesions on FNAC. The number of ME cells
may be helpful in distinguishing between PBD versus
DCIS and invasive carcinoma on FNAC smears. However,
in routine reporting, it is not possible to quantitate the
number of ME cells and probably a subjective assessment
could be done along with other cytology features.
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